{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:45:33Z","timestamp":1789753533695,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.intimp.2022.108688","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T05:21:43Z","timestamp":1647062503000},"page":"108688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The intrapleural administration with thymic peptides in malignant pleural effusion: A clustered systematic review and meta-analysis"],"prefix":"10.1016","volume":"107","author":[{"given":"Cheng-Qiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Shu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"140","key":"10.1016\/j.intimp.2022.108688_b0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: from bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur. Respir. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.108688_b0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-0039-1698285","article-title":"Management of Malignant Pleural Effusions-What Is New","volume":"40","author":"Thomas","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"11 Suppl","key":"10.1016\/j.intimp.2022.108688_b0015","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/1097-0142(19841201)54:2+<2795::AID-CNCR2820541427>3.0.CO;2-E","article-title":"Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer","volume":"54","author":"Oldham","year":"1984","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2022.108688_b0020","first-page":"2229","article-title":"Biological response modifiers used in cancer biotherapy","volume":"32","author":"Kuroki","year":"2012","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.108688_b0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4399","key":"10.1016\/j.intimp.2022.108688_b0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.451537","article-title":"A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin","volume":"204","author":"Goldstein","year":"1979","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2022.108688_b0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1515\/bchm2.1983.364.2.933","article-title":"Immuno-regulating peptides, I. Synthesis and structure-activity relationships of thymopentin analogs","volume":"364","author":"Kisfaludy","year":"1983","journal-title":"Hoppe Seylers Z Physiol. Chem."},{"key":"10.1016\/j.intimp.2022.108688_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105747","article-title":"Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines","volume":"75","author":"Zeng","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"05","key":"10.1016\/j.intimp.2022.108688_b0045","first-page":"618","article-title":"Clinical efficacy and safety evaluation of thymic peptide in patients of diabetes mellitus with tuberculosis","volume":"41","author":"Wang","year":"2018","journal-title":"J. Zunyi Med. Univ."},{"issue":"1","key":"10.1016\/j.intimp.2022.108688_b0050","first-page":"36","article-title":"Thymosin combined with oxaliplatin in the treatment of lung cancer complicated with malignant pleuraI effusion: A meta-analysis","volume":"36","author":"Lu","year":"2019","journal-title":"J. Guangxi Med. Univ."},{"issue":"4","key":"10.1016\/j.intimp.2022.108688_b0055","first-page":"Cd010529","article-title":"Interventions for the management of malignant pleural effusions: a network meta-analysis","volume":"4","author":"Dipper","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2022.108688_b0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of Malignant Pleural Effusions. An Official ATS\/STS\/STR Clinical Practice Guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108688_b0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccm.2020.02.009","article-title":"Management of Malignant Pleural Effusions","volume":"41","author":"Shafiq","year":"2020","journal-title":"Clin. Chest Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.108688_b0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17476348.2020.1793672","article-title":"Multidisciplinary approaches to the management of malignant pleural effusions: a guide for the clinician","volume":"14","author":"Banka","year":"2020","journal-title":"Expert Rev. Respir. Med"},{"issue":"12","key":"10.1016\/j.intimp.2022.108688_b0075","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/(SICI)1097-0142(19961215)78:12<2498::AID-CNCR8>3.0.CO;2-G","article-title":"Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline","volume":"78","author":"Emad","year":"1996","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2022.108688_b0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/COC.0b013e3181aacbbf","article-title":"Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches","volume":"33","author":"Lombardi","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108688_b0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ejcts.2005.12.025","article-title":"The evidence on the effectiveness of management for malignant pleural effusion: a systematic review","volume":"29","author":"Tan","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.intimp.2022.108688_b0090","article-title":"Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.108688_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153260","article-title":"Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials","volume":"76","author":"Xiao","year":"2020","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2022.108688_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4328-3","article-title":"Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion","volume":"18","author":"Fuhong","year":"2018","journal-title":"BMC Cancer"},{"issue":"B11","key":"10.1016\/j.intimp.2022.108688_b0105","first-page":"232","article-title":"Evaluation and Analysis on the use of bioimmunotherapy for cancer outpatients in a provincial hospital from 2013 to 2014","volume":"22","author":"Zhang","year":"2015","journal-title":"Chin. J. Cancer Prev. Treat."},{"issue":"10","key":"10.1016\/j.intimp.2022.108688_b0110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/13696998.2020.1801455","article-title":"Rational drug use in hospital settings - areas that can be changed","volume":"23","author":"Religioni","year":"2020","journal-title":"J. Med. Econ."},{"issue":"10090","key":"10.1016\/j.intimp.2022.108688_b0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(16)32585-5","article-title":"Evidence for overuse of medical services around the world","volume":"390","author":"Brownlee","year":"2017","journal-title":"Lancet"},{"issue":"10090","key":"10.1016\/j.intimp.2022.108688_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0140-6736(16)32586-7","article-title":"Levers for addressing medical underuse and overuse: achieving high-value health care","volume":"390","author":"Elshaug","year":"2017","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.intimp.2022.108688_b0125","first-page":"170","article-title":"Clinical observation of Oxaliplatin combined with Thymosin in the treatment of lung cancer complicated with malignant pleural effusion","volume":"18","author":"Li","year":"2020","journal-title":"Guide China Med."},{"issue":"97","key":"10.1016\/j.intimp.2022.108688_b0130","first-page":"220","article-title":"Clinical value of Oxaliplatin combined with Thymosin in the treatment of lung cancer complicated with malignant pleural effusion","volume":"20","author":"Wang","year":"2020","journal-title":"World Latest Med. Inform."},{"issue":"01","key":"10.1016\/j.intimp.2022.108688_b0135","first-page":"69","article-title":"Short term efficacy and safety of weekly Cisplatin combined with Thymosin intrapleural perfusion in the treatment of non-small cell lung cancer with malignant pleural effusion","volume":"14","author":"Hou","year":"2021","journal-title":"Chin. J. Clin. Ration Drug Use"},{"issue":"2","key":"10.1016\/j.intimp.2022.108688_b0140","first-page":"127","article-title":"Evolution of Levels of Evidence and Strength of Recommendations in Medical Research","volume":"8","author":"Chen","year":"2008","journal-title":"Chin. J. Evid. Based Med."},{"key":"10.1016\/j.intimp.2022.108688_b0145","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2022.108688_b0150","unstructured":"J.P.T. Higgins, J. Thomas, J. Chandler, L.T.M. Cumpston, M.J. Page, W.V. (editors), Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021), Cochrane Available from www.training.cochrane.org\/handbook (2021)."},{"issue":"1","key":"10.1016\/j.intimp.2022.108688_b0155","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"5","key":"10.1016\/j.intimp.2022.108688_b0160","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/1097-0142(197611)38:5<1903::AID-CNCR2820380506>3.0.CO;2-A","article-title":"Intracavitary bleomycin in the management of malignant effusions","volume":"38","author":"Paladine","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2022.108688_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"issue":"8","key":"10.1016\/j.intimp.2022.108688_b0170","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.108688_b0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2022.108688_b0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.intimp.2022.108688_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104637","article-title":"Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials","volume":"153","author":"Xiao","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.108688_b0190","doi-asserted-by":"crossref","unstructured":"Z. Xiao, Y. Jiang, X.F. Chen, C.Q. Wang, W.H. Xu, Y. Liu, S.S. Hu, X.R. Huang, L.J. Shan, Y.H. Tang, Y.B. Yang, J.H. Feng, X. Xiao, X.F. Li, The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials, Clin. Ther. 42(3) (2020) 515-543 e31.","DOI":"10.1016\/j.clinthera.2020.01.011"},{"key":"10.1016\/j.intimp.2022.108688_b0195","doi-asserted-by":"crossref","unstructured":"X. Sun, M. Briel, S.D. Walter, G.H. Guyatt, Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses, Bmj 340 (2010) c117.","DOI":"10.1136\/bmj.c117"},{"issue":"7650","key":"10.1016\/j.intimp.2022.108688_b0200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.intimp.2022.108688_b0205","first-page":"43","article-title":"Clinical observation of combined intropleural therapy with Interleukin-2 plus Cisplatin for pulmonary carcinomatous pIeural effusion","volume":"5","author":"Gao","year":"2000","journal-title":"Chin. Clinl. Oncol."},{"key":"10.1016\/j.intimp.2022.108688_b0210","unstructured":"M. Zhao, F. Lang, J. Ma, J. Sun, RT-Term of conblnation of Thymlsin and Cargopd latin in the shorte treatment of mailignant pleural effusion, Chin. J. Cancer Prev. Treat. 9(2) (2002) 189-189."},{"key":"10.1016\/j.intimp.2022.108688_b0215","unstructured":"F. Li, Z. Wang, Y. Xue, Cisplatin with Thymic peptide for malignant pleural effusion in patients with lung cancer by intrathoracic injection: a clinical study of 21 cases, Shandong Med. J. 44(12) (2004) 26-26."},{"issue":"2","key":"10.1016\/j.intimp.2022.108688_b0220","first-page":"141","article-title":"The curative effect of Cisplatin on malignant pleural effusion combined with Thymopentin in human","volume":"20","author":"Lin","year":"2005","journal-title":"J. North Sichuan Med. Coll."},{"issue":"5","key":"10.1016\/j.intimp.2022.108688_b0225","first-page":"300","article-title":"Clinical efficacy of Carboplatin with Thymopentin for malignant pleural effusion in lung cancer","volume":"41","author":"Gao","year":"2010","journal-title":"New Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.108688_b0230","first-page":"658","article-title":"Clinical study for malignant pleural effusion with Thymosin \u03b11","volume":"23","author":"Guo","year":"2011","journal-title":"Med. J. West China"},{"key":"10.1016\/j.intimp.2022.108688_b0235","unstructured":"R. He, Effect of Carboplatin combined with Thymopentin in the treatment of malignant pleural effusion in patients with lung cancer, J. North Pharm. 8(06) (2011) 11-11."},{"issue":"13","key":"10.1016\/j.intimp.2022.108688_b0240","first-page":"86","article-title":"Cisplatin with Thymopentin for malignant pleural effusion in patients with lung cancer: a clinical study of 76 cases","volume":"19","author":"Mo","year":"2012","journal-title":"China Modern Med."},{"key":"10.1016\/j.intimp.2022.108688_b0245","unstructured":"Z. Wu, Clinical efficacy of Thymosin with Cisplatin in malignant pleural effusion, Chin. J. Clin. Rational Drug Use 5(35) (2012) 86-86."},{"issue":"14","key":"10.1016\/j.intimp.2022.108688_b0250","first-page":"84","article-title":"Clinical study of Cisplatin and Thymopentin for malignant pleural effusion in patients with lung cancer by intrapleural infusion","volume":"39","author":"Zhang","year":"2012","journal-title":"Chin. J. Pract. Med."},{"issue":"23","key":"10.1016\/j.intimp.2022.108688_b0255","first-page":"105,107","article-title":"Clinical efficacy of Thymosin with Cisplatin in the treatment of malignant pleural effusion","volume":"32","author":"Tan","year":"2013","journal-title":"China Foreign Med. Treat"},{"issue":"20","key":"10.1016\/j.intimp.2022.108688_b0260","first-page":"1867","article-title":"Clinical observation of Cisplatin combined with Thymosin \u03b1 1 for malignant pleural effusion with intrapleural infusion","volume":"25","author":"Huo","year":"2014","journal-title":"China Pharm."},{"issue":"13","key":"10.1016\/j.intimp.2022.108688_b0265","first-page":"1994","article-title":"Clinical efficacy of Oxaliplatin with Thymosin for malignant pleural effusion in patients with lung cancer","volume":"37","author":"Liang","year":"2015","journal-title":"Hebei Med. J."},{"issue":"27","key":"10.1016\/j.intimp.2022.108688_b0270","first-page":"3767","article-title":"Clinical observation of Oxaliplatin combined with Thymosin in the treatment of lung cancer with malignant pleural effusion","volume":"27","author":"Yang","year":"2016","journal-title":"China Pharm."},{"key":"10.1016\/j.intimp.2022.108688_b0275","unstructured":"J. Pang, Application effect of Oxaliplatin combined with Thymosin in lung cancer with malignant pleural effusion, J. Clin. Med. Lit. 4(14) (2017) 2705-2705."},{"issue":"04","key":"10.1016\/j.intimp.2022.108688_b0280","first-page":"88","article-title":"Clinical efficacy of Thymic peptide with Cisplatin in the treatment of malignant pleural effusion through intrapleural infusion","volume":"23","author":"Su","year":"2017","journal-title":"Hennan J. Surgery"},{"issue":"12","key":"10.1016\/j.intimp.2022.108688_b0285","first-page":"68","article-title":"Therapeutic effect of Oxaliplatin combined with Thymosin in treatment of lung cancer complicated with malignant pleural effusion","volume":"37","author":"Ying","year":"2017","journal-title":"Chin. J. Biochem. Pharm."},{"issue":"64","key":"10.1016\/j.intimp.2022.108688_b0290","first-page":"12621","article-title":"Curative effect of Lobaplatin combined with Thymosin in the treatment of lung cancer with malignant pleural effusion","volume":"4","author":"Yu","year":"2017","journal-title":"J. Clin. Med. Lit."},{"issue":"10","key":"10.1016\/j.intimp.2022.108688_b0295","first-page":"207","article-title":"Efficacy and safety of Oxaliplatin combined with Thymosin in the treatment of lung cancer with malignant pleural effusion","volume":"1","author":"Yu","year":"2017","journal-title":"J. Imaging Res. Med. Appl."},{"issue":"64","key":"10.1016\/j.intimp.2022.108688_b0300","first-page":"12620","article-title":"Efficacy evaluation of Oxaliplatin combined with Thymosin in the treatment of lung cancer with malignant pleural effusion","volume":"4","author":"Zhao","year":"2017","journal-title":"J. Clin. Med. Lit."},{"issue":"9","key":"10.1016\/j.intimp.2022.108688_b0305","first-page":"1794","article-title":"Clinical efficacy of Thymosin with Oxaliplatin for malignant pleural effusion in patients with lung cancer","volume":"14","author":"Zhou","year":"2017","journal-title":"Anti Infect. Pharm."},{"issue":"3","key":"10.1016\/j.intimp.2022.108688_b0310","first-page":"240","article-title":"Clinical efficacy of Thymosin with Oxaliplatin for malignant pleural effusion in patients with lung cancer by intrathoracic injection","volume":"31","author":"Chen","year":"2018","journal-title":"J. Basic Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108688_b0315","first-page":"252","article-title":"Efficacy of Oxaliplatin combined with Thymic peptide in the treatment of malignant pleural effusion by intrapleural perfusion and effects on immune function in elderly patients with lung cancer","volume":"32","author":"Liu","year":"2018","journal-title":"Pract. Geriatr."},{"issue":"22","key":"10.1016\/j.intimp.2022.108688_b0320","first-page":"170","article-title":"Clinical efficacy of Thymic peptide with Oxaliplatin for malignant pleural effusion in patients with lung cancer","volume":"8","author":"Lu","year":"2018","journal-title":"J. Frontiers Med."},{"key":"10.1016\/j.intimp.2022.108688_b0325","unstructured":"Z. Wang, L. Fang, M. Jiang, X. Yi, Effects of Thymic peptide combined with Oxaliplatin on clinical efficacy,serum inflammatory factors and T lymphocyte in patients with malignant pleural effusion of lung cancer, J. North Sichuan Med. Coll. 33(1) (2018) 94-97,104."},{"issue":"17","key":"10.1016\/j.intimp.2022.108688_b0330","first-page":"46","article-title":"Clinical efficacy of Thymic peptide with Oxaliplatin for malignant pleural effusion in patients with lung cancer","volume":"10","author":"Yu","year":"2018","journal-title":"China rural health"},{"issue":"10","key":"10.1016\/j.intimp.2022.108688_b0335","first-page":"121","article-title":"Curative effect of Thymic peptide combined with Lobaplatin in patients with malignant pleural effusion of lung cancer and effect on the serum inflammatory factor and T lymphocytes","volume":"3","author":"Zhao","year":"2018","journal-title":"Systems Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.108688_b0340","first-page":"5","article-title":"Effect of Oxaliplatin combined with Thymosin in the treatment of malignant pleural effusion caused by lung cancer","volume":"26","author":"Chen","year":"2019","journal-title":"Chin. J. Rural Med. Pharm."},{"issue":"15","key":"10.1016\/j.intimp.2022.108688_b0345","first-page":"44","article-title":"Clinical observation of Oxaliplatin combined with Thymosin in the treatment of lung cancer complicated with malignant pleural effusion","volume":"3","author":"Fan","year":"2019","journal-title":"Modern Med. Health Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.108688_b0350","first-page":"74","article-title":"Clinical efficacy of Oxaliplatin combined with Thymosin perfusion in the treatment of lung cancer with malignant pleural effusion","volume":"12","author":"Luo","year":"2019","journal-title":"Chin. J. Clin. Rational Drug Use"},{"issue":"21","key":"10.1016\/j.intimp.2022.108688_b0355","first-page":"76","article-title":"Clinical analysis of Oxaliplatin combined with Thymosin in the treatment of lung cancer with malignant pleural effusion","volume":"11","author":"Yang","year":"2019","journal-title":"China Rural Health"},{"key":"10.1016\/j.intimp.2022.108688_b0360","unstructured":"Y.-P. Sun, C.-Q. Wang, L. Chen, N.-N. Li, X.-S. Yao, Z. Xiao, Effectiveness and safety of interleukin-2 plus cisplatin for treating malignant pleural effusion:a meta analysis, Chongqing Med. 46(1) (2017) 84-89,93."},{"issue":"4","key":"10.1016\/j.intimp.2022.108688_b0365","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/1759-7714.12354","article-title":"Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion","volume":"7","author":"Yoon","year":"2016","journal-title":"Thorac Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:36:11Z","timestamp":1761586571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922001722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":73,"alternative-id":["S1567576922001722"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108688","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108688"}}